Biotechnology company developing bioengineered human tissue products for vascular trauma, dialysis access, and regenerative medicine.
Profile & Fundamentals
Humacyte: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Humacyte Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Company profile record
Humacyte Inc
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Humacyte Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 2525 East North Carolina Highway 54, Durham, NC, United States, 27713
Leadership & scale
- Chief executive
- Dr. Laura E. Niklason M.D., Ph.D.
- CEO year born
- 1963
- Full-time employees
- 184
- Fiscal year end
- December
- IPO date
- 2021-08-26
Fundamentals snapshot
- Market Cap
- USD 111.9M
- P/E
- --
- Revenue (Q2 26)
- USD 406.0K
- Profit (Q2 26)
- USD -36.8M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 2.0M
- Shares in public float
- 251M
- Insider ownership
- 5.67%
Reporting & identifiers
- Symbol
- HUMA.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US44486Q1031
- Asset ID
- equity_a665b955-e456-5ac0-bc95-6cd5c0083913
Ownership
Shares Outstanding
Latest: 234.2M | Max: 234.2M | Min: 103.0M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
107.19%
251.0M latest reported shares
Insider Ownership
5.67%
Latest reported insider stake
Short Float
0.12%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2020-01-01 | 103,003,400 |
| 2021-01-01 | 104,743,900 |
| 2022-01-01 | 103,162,200 |
| 2023-01-01 | 103,607,600 |
| 2024-01-01 | 118,479,100 |
| 2025-01-01 | 158,160,500 |
| 2026-01-01 | 234,182,300 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 12,316,955 | 4.43% | 2026-03-31 |
| Antipodes Partners Limited | 10,103,647 | 3.64% | 2026-06-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 7,716,766 | 2.78% | 2026-08-31 |
| Vanguard Capital Management, LLC | 7,158,162 | 2.58% | 2026-03-31 |
| Great Point Partners LLC | 3,750,000 | 1.35% | 2026-06-30 |
| Geode Capital Management, LLC | 3,658,108 | 1.32% | 2026-03-31 |
| State Street Corp | 3,043,929 | 1.1% | 2026-03-31 |
| UBS Group AG | 2,782,070 | 1% | 2026-03-31 |
| Woodline Partners LP | 2,002,582 | 0.72% | 2026-03-31 |
| AQR Capital Management LLC | 1,924,691 | 0.69% | 2026-03-31 |
| Millennium Management LLC | 1,909,049 | 0.69% | 2026-06-30 |
| iShares Biotechnology ETF | 1,834,396 | 0.66% | 2026-08-31 |
| Citadel Advisors Llc | 1,443,376 | 0.52% | 2026-06-30 |
| Vanguard Portfolio Management, LLC | 1,417,825 | 0.51% | 2026-03-31 |
| Charles Schwab Investment Management Inc | 1,291,345 | 0.46% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Humacyte's latest financial results reflect an early commercial launch burdened by heavy development costs. Trailing twelve-month revenue reached just $2.12 million, while operating losses mounted to $111 million and net losses totaled $96.7 million. Although product sales improved compared to pre-approval periods, second-quarter 2026 revenue of $406,000 shows that initial commercial sales in vascular trauma remain modest. Beneath headline accounting swings, which previously included non-cash fair-value gains on warrant liabilities, the underlying business burns substantial capital. Free cash flow of negative $97.6 million over the trailing twelve months confirms that commercial sales currently cover less than three percent of operating expenses, leaving the business dependent on outside capital.
Humacyte's latest financial results reflect an early commercial launch burdened by heavy development costs. Trailing twelve-month revenue reached just $2.12 million, while operating losses mounted to $111 million and net losses totaled $96.7 million. Although product sales improved compared to pre-approval periods, second-quarter 2026 revenue of $406,000 shows that initial commercial sales in vascular trauma remain modest. Beneath headline accounting swings, which previously included non-cash fair-value gains on warrant liabilities, the underlying business burns substantial capital. Free cash flow of negative $97.6 million over the trailing twelve months confirms that commercial sales currently cover less than three percent of operating expenses, leaving the business dependent on outside capital.
Revenue, Net Income, and Free Cash Flow
Latest: USD 2.0M | Max: USD 6.2M | Min: USD -148.7M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Reported profitability margins remain deeply negative due to severe fixed-cost underutilization. In the second quarter of 2026, cost of goods sold reached $1.2 million against product revenue of only $406,000, burdened by idle plant overhead and a $700,000 inventory reserve charge. Consequently, gross and operating margins remain capped deep below negative 300 percent. This margin distortion is structural at low production volumes rather than a flaw in biological technology. Growing living tissue inside automated bioreactors requires continuous cleanroom maintenance, sterility testing, and regulatory monitoring regardless of output. True gross profit margins exceeding 60 percent cannot emerge until high-volume hemodialysis adoption absorbs fixed plant expenses across thousands of manufactured units.
Reported profitability margins remain deeply negative due to severe fixed-cost underutilization. In the second quarter of 2026, cost of goods sold reached $1.2 million against product revenue of only $406,000, burdened by idle plant overhead and a $700,000 inventory reserve charge. Consequently, gross and operating margins remain capped deep below negative 300 percent. This margin distortion is structural at low production volumes rather than a flaw in biological technology. Growing living tissue inside automated bioreactors requires continuous cleanroom maintenance, sterility testing, and regulatory monitoring regardless of output. True gross profit margins exceeding 60 percent cannot emerge until high-volume hemodialysis adoption absorbs fixed plant expenses across thousands of manufactured units.
Profitability Margins
Latest: <-100.0% | Max: <-100.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
-736.5%
Gross profit / revenue
Operating Margin
-5271.7%
Operating income / revenue
Net Margin
-2003.6%
Net income / revenue
FCF Margin
-5197.5%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2019-12-31 | 6,187,000 | -85,422,000 | -79,912,000 |
| 2020-12-31 | 1,491,000 | -66,524,000 | -55,886,000 |
| 2021-12-31 | 1,263,000 | -26,477,000 | -81,410,000 |
| 2022-12-31 | 1,565,000 | -11,965,000 | -72,177,000 |
| 2023-12-31 | 0 | -110,776,000 | -75,585,000 |
| 2024-12-31 | 0 | -148,701,000 | -99,694,000 |
| 2025-12-31 | 2,038,000 | -40,833,000 | -105,926,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2019-12-31 | -1,121.97 | -1,385.02 | -1,380.67 | -1,291.61 |
| 2020-12-31 | -3,526.96 | -4,332.66 | -4,461.7 | -3,748.22 |
| 2021-12-31 | -4,756.77 | -6,429.77 | -2,096.36 | -6,445.76 |
| 2022-12-31 | -427.48 | -5,404.35 | -764.54 | -4,611.95 |
| 2023-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2024-12-31 | Not reported | Not reported | Not reported | Not reported |
| 2025-12-31 | -736.46 | -5,271.69 | -2,003.58 | -5,197.55 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-10-01.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.